Rankings
▼
Calendar
SUPN Q1 2025 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
SUPN
Supernus Pharmaceuticals, Inc.
$3B
Q1 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$150M
+4.3% YoY
Gross Profit
$134M
89.5% margin
Operating Income
-$10M
-6.8% margin
Net Income
-$12M
-7.9% margin
EPS (Diluted)
$-0.21
QoQ Revenue Growth
-14.0%
Cash Flow
Operating Cash Flow
$31M
Free Cash Flow
$30M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$317M
Stockholders' Equity
$1.0B
Cash & Equivalents
$116M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$150M
$144M
+4.3%
Gross Profit
$134M
$127M
+5.3%
Operating Income
-$10M
-$3M
-225.3%
Net Income
-$12M
$124,000
-9637.9%
Revenue Segments
Product
$142M
49%
Qelbree
$65M
22%
GOCOVRI
$31M
11%
APOKYN
$15M
5%
Trokendi Xr
$13M
4%
Oxtellar X R
$10M
3%
Manufactured Product, Other
$9M
3%
Royalty, License And Other Revenue
$8M
3%
← FY 2025
All Quarters
Q2 2025 →